Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 103, Issue 29, Pages 10834-10839Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.0603940103
Keywords
meningococcus B; reverse vaccinology
Categories
Funding
- NIAID NIH HHS [R01 AI046464-01A1, R01 AI046464] Funding Source: Medline
Ask authors/readers for more resources
Meningitis and sepsis caused by serogroup B meningococcus are two severe diseases that still cause significant mortality. To date there is no universal vaccine that prevents these diseases. In this work, five antigens discovered by reverse vaccinology were expressed in a form suitable for large-scale manufacturing and formulated with adjuvants suitable for human use. The vaccine adjuvanted by aluminum hydroxide induced bactericidal antibodies in mice against 78% of a panel of 85 meningococcal strains representative of the global population diversity. The strain coverage could be increased to 90% and above by the addition of CpG oligonucleoticles or by using MF59 as adjuvant. The vaccine has the potential to conquer one of the most devastating diseases of childhood.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available